Drugs
-
Rebate debate redux: Revisiting 340B drug pricing
In a high-stakes struggle over the fate of the popular drug pricing program, neither the Trump administration nor safety-net hospital groups seem willing to cede the field.
-
A federal reset for the hemp products market
A Senate agreement to restart federal operations also introduces a stringent framework for hemp-derived cannabinoid products, with significant implications for compliance teams across a $28-billion sector.
-
States fight “most favored” clause in Sandoz deal
Challenge filed in Federal Court by 20 states.